Medical Epigenetics
Prof. Dr. Marc Timmers
Our group studies transcriptional regulation in relation to chromatin modifications which are relevant to human diseases. In particular, we focus on the MLL complexes which deposit histone methylation and regulate the activity of gene enhancers and gene promoters. Genes encoding integral subunits of the MLL3 and MLL4 complexes display the highest mutational frequency in bladder cancer. This type of tumor is characterized by a strong gender imbalance and we are examining the mechanistic basis for this. Besides these molecular studies, we are performing both genetic and chemical screens to determine targetable vulnerabilities of bladder cancer cell lines and primary 2D and 3D cultures from bladder cancers with the aim to develop new treatment options for this disease. The menin subunit of the MLL1/MLL2 complexes has become a major focus for leukemia research as chemical menin-MLL inhibitors display remarkable efficacy in certain types of AML and are expected to receive FDA approval for treatment soon. All cellular and epigenetic signaling culminates in the loading of RNA polymerase II to specific sets of gene promoters. The basal transcription factor TFIID plays a coordinating role in setting transcription initiation frequencies. We are examining the chromatin aspects on the dynamic regulation of TFIID activity.
In general, our studies of gene transcription and chromatin regulation employ combinations of cell biology, molecular biology, proteomics, genomics, automated microscopy, bioinformatics approaches and chemical and genetic libraries targetting epigenetics.
Future projects and goals
We aim to identify epigenetic mechanisms and therapeutic vulnerabilities of bladder cancer. Using KDM6A/UTX and UTY as model genes, we want to understand the gender disparity in bladder cancer. The MLL3 and MLL4 histone H3K4 methylase complexes are central in our mechanistic studies. The epigenetic signalling from MLL complexes towards the basal transcription factor TFIID and its regulation has our special interest.
Prof. Dr. Marc Timmers
Professur - Partnerstandort Freiburg
Medical Center-University of Freiburg Department of Urology,
Zentrale Klinische Forschung (ZKF)